Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2.

Clinics (Sao Paulo, Brazil) - 1 Feb 2006

Toledo Sergio Pereira de Almeida, dos Santos Marcelo Augusto Cortina Gonçalves, Toledo Rodrigo de Almeida, Lourenço Delmar Muniz

Abstract excerpt

Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant disease characterized by the presence of medullary thyroid carcinoma, primary hyperparathyroidism, and pheochromocytoma. Multiple endocrine neoplasia type 2 is still an underdiagnosed, or late-diagnosed condition in many areas of the world. Since 1993, when the first missense RET proto-oncogene (RET) mutations were reported in MEN2, up to 46...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Medullary
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Multiple Endocrine Neoplasia Type 2a

Share to Pheochromocytoma

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-ret

Share to Thyroid Neoplasms

Share to Thyroidectomy

Source

Identifiers

PMID: 16532227
DOI: /S1807-59322006000100011

Genes

RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2.PMID 16532227Read ↗

Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid CarcinomaSemantic proximity Read ↗

RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.Semantic proximity Read ↗

Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.Semantic proximity Read ↗

RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.Semantic proximity Read ↗

Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management.Semantic proximity Read ↗

Multiple endocrine neoplasia type 2: 2007 update.Semantic proximity Read ↗

Clinical significance of RET mutation screening in a pedigree of multiple endocrine neoplasia type 2A.Semantic proximity Read ↗

Multiple endocrine neoplasia type 2.Semantic proximity Read ↗

Utility of RET mutation analysis in multiple endocrine neoplasia type 2.Semantic proximity Read ↗

Molecular advances in medullary thyroid cancer diagnostics.Semantic proximity Read ↗

RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.Semantic proximity Read ↗

Spectrum of Germline RET Variants Identified by Targeted Sequencing and Associated Multiple Endocrine Neoplasia Type 2 Susceptibility in ChinaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.